Conoa-B (02162) rose more than 5% in the morning. As of press release, it was up 3.97% to HK$39.25, with a turnover of HK$81.3695 million.
The Zhitong Finance App learned that Conoa-B (02162) rose more than 5% in the morning. As of press release, it had risen 3.97% to HK$39.25, with a turnover of HK$81.3695 million.
According to the news, Connoya announced that the marketing application for the new drug supivacumab (trade name: Kang Yueda) has recently been approved by the China National Drug Administration. The indication is moderate to severe atopic dermatitis in adults. Currently, the application for marketing of a new drug with spoximab to treat seasonal allergic rhinitis and chronic sinusitis with nasal polyps has been accepted.
Guotai Junan pointed out that CM310 (supibalimab, trade name: Kang Yueda) for adults with moderate to severe AD was approved and marketed by CDE on September 12, becoming the first IL-4R monoclonal antibody approved in China and the second in the world. Phase III clinical trials have shown good efficacy and safety. Currently, the commercial team consists of nearly 200 people, which is expected to rapidly advance sales. Considering the early commercialization of CM310, Connoah's 2024 revenue forecast was raised by 0.197 billion yuan, maintaining the 2025-2026 revenue forecast of 0.526/1.441 billion yuan.